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Aims: Prognostic analysis of hepatocellular carcinoma (HCC) in the cirrhotic patient undergoing hepatic resection
is necessary in order to determine the clinical eﬀect of hepatectomy on prognosis.
Patients and methods: Univariate and multivariate retrospective analyses were performed in 51 cirrhotic patients (38
men, 13 women; mean age 65 years, range 43–81 years) with supervening HCC undergoing hepatic resection between
January 1993 and December 1997.
Results: Segmental liver resection was performed in 39 patients (76%) with non-anatomical (wedge) resections in the
remainder of cases. The post-operative mortality rate was 8%. The tumours recurred in 23 patients (45%), with 12
patients (52% of recurrences) recurring within 1 year of surgery and 22 patients (96% of recurrences) within 3 years.
Recurrent disease was most frequently intrahepatic (22 patients). Significant risk factors for recurrence were micro/
macro vascular invasion, and symptoms.
Conclusions: The recurrence rate of hepatocellular carcinoma in patients with cirrhosis undergoing surgical resection
alone is high and actuarial survival at 4 years is low. Other approaches to the treatment of hepatocellular carcinoma
in patients with cirrhosis require consideration.  2000 Harcourt Publishers Ltd
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Introduction Patients and methods
The prevalence of cirrhosis in hepatocellular carcinoma
Fifty-one cirrhotic patients (38 men, 13 women; mean age(HCC) patients ranges from 60 to 90%.1 Frequent
65 years, range 43–81 years) underwent hepatic resectionmonitoring with ultrasonography (US) and -fetoprotein
for supervening HCC in the Department of Emergency(AFP) levels have made it possible to discover small tumours
Surgery at the University of Milan between January 1993(Ζ2 cm in maximal diameter) in patients with cirrhosis
and December 1997. Their clinical features and demographicand chronic viral hepatitis.2 Surgical resection with partial
characteristics are summarized in Table 1.hepatic resection or liver transplantation are the only
Thirty-eight patients (74%) were asymptomatic, withpotentially curative treatments.3–6 However, hepatic
HCC being discovered by US during routine follow-up forresection can only be oﬀered to patients with good liver
cirrhosis. The remainder of cases (26%) were symptomatic.function and well-defined, solitary tumours treatable with
Abdominal pain and upper gastrointestinal haemorrhagelimited hepatic resection. Liver transplantation is the only
were the most frequently presenting symptoms. Nineteenoption in patients with poor liver function or in non-
patients (37%) had hepatitis C virus, 11 (21%) hepatitis Cresectable tumour(s), provided extrahepatic malignancy has
plus hepatitis B virus, 10 (20%) isolated hepatitis B virus,been excluded.
eight (16%) alcoholic cirrhosis and three (6%) cryptogenicThe present study details experience in our institution
cirrhosis. Each case was classified according to thegained in the surgical resection of HCC in patients with
Child–Pugh criteria for hepatic functional reserve.7 Allcirrhosis.
patients were also evaluated with indocyanine green
retention8 at 15 min as predictor of liver reserve. Thirty-
eight patients (74%) were in Child’s group A, 12 (24%) in
Child’s group B, and one (2%) in Child’s group C.∗Correspondence to: Antonio Chiappa, MD, Dept. of General
US before operation detected a single nodule in 31 patientsSurgery, University of Milan, European Institute of Oncology, V.
Ripamonti, 435, 21100, Milan, Italy. (61%), with a mean size of 5±4 cm in maximal diameter
0748–7983/00/040387+06 $35.00/0  2000 Harcourt Publishers Ltd
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Table 1. Clinical and surgical features for the 51 cirrhotic patients Table 2. Histopathological features of resected tumours in cirrhotic
patientswith supervening HCC undergoing resection
Mean (SD) age (years) 65 (8) (range 43–81) Mean (SD) tumour size (cm) 6 (4)
Sex (m:f) 38:13 (2.9:1) (ratio) Ζ2 cm 6 (12)
Aetiology 2–5 cm 31 (61)
Post-necrotic HCV 19 (37) >5 cm 14 (27)
Post-necrotic HBV and HCV 11 (21) Number of tumours
Post-necrotic HBV 10 (20) One tumour 42 (82)
Alcoholic 8 (16) More than one tumour 9 (18)
Other 3 (6) Satellite nodulesChild–Pugh classification Absent 37 (73)A 38 (74)
Present 14 (27)B 12 (24)
CapsuleC 1 (2)
Present 15 (29)HCC symptomatic
Absent 36 (71)Yes 13 (26)
Vascular invasionNo 38 (74)
Absent 32 (63)AFP (ng/ml)
Present 19 (37)<20 ng/ml 19 (37)
[20 ng/ml 32 (63) Hepatic margin
Types of hepatic resection Involved 0
Segmentectomies 19 (37) Clear margin (<1 cm) 12 (24)
Bisegmentectomies 11 (22) Clear margin ([1 cm) 39 (76)
Non-segmental resections 12 (23)
Major hepatectomies 9 (18) Values in parentheses are percentages. SD, standard deviation.
Values in parentheses are percentages. SD, standard deviation;
HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, -fetoprotein
(normal value: 0–12 ng/ml).
relation to clinical and pathological characteristics of the
tumour and type of cirrhosis was evaluated. The parameters
used in the univariate analysis were as follows: sex, age,and two nodules of HCC in seven patients (14%) with a
cirrhosis aetiology, presence or absence of alcoholism,mean size of 6±3 cm. Abdominal computed tomography
hepatitis C virus, hepatitis B surface antigen, symptoms,(CT) with intravenous contrast was performed in 45 patients
AFP level, type of resection and hepatic resection margin(88%) and showed one main tumour in 35 cases (78%), two
(more or less than 1 cm), tumour size and number, type ofseparate nodules in nine (20%), and three nodules in one
tumour, satellite nodules, tumour diﬀerentiation, tumourcase (2%). Satellite lesions, defined as a minute contrast
capsule, capsule invasion, vascular invasion, and presenceenhancement near the primary lesion, were occasionally
of associated dysplasia.detected in 12 subjects (26%).
Segmental resection was performed in 39 patients (76%),
while the remaining 12 patients (24%) underwent non-
Analysis of the dataanatomical (wedge) resection. Three patients (6%) had
repeat hepatic resections because of tumour recurrence
Overall and disease-free survival analyses were conductedin the hepatic remnant. Intra-operative ultrasonography
using the Kaplan–Meier method,11 with comparisons(IOUS) was used in 31 patients (61%). At operation the
between groups performed by the log-rank test.12 Disease-tumour could not be located by inspection or palpation in
free survival was estimated from the date of the hepatic12 patients (24%) but was found by IOUS. This examination
resection to the date of diagnosis of recurrent disease usingdetected additional nodules in one patient who had been
US, CT scan, hepatic angiography or biopsy. Multivariatediagnosed as having a solitary tumour before surgery.
analysis using Cox’s logistic regression technique13 wasCirrhosis was histologically confirmed in all patients.
employed for variables found to be significant on univariatePatients were staged according to the UICC TNM
analysis. Statistical significance is recorded for P-valuesclassification for HCC.9
<0.05.Tumour diﬀerentiation was recorded according to the
standard grading of Edmonson and Steiner.10 Thirty-nine
patients had a clear surgical margins of more than 1 cm, and
Results12 patients had a clear surgical margin of less than 1 cm.
There were no patients with hepatic resection margin involved.
There were four peri-operative deaths (8%). Three patientsAll patients with HCC complicating their cirrhosis were
died from hepatic failure and one from post-operativeresected for cure. The mean tumour size was 6±4 cm in
myocardial infarction. Post-operative ascites occurred inmaximal diameter (Table 2). According to the UICC TNM
seven patients with progressive hepatorenal syndrome instaging, seven patients (14%) were stage 1, 18 (35%) stage
one case. Major peri-operative complications occurred in2, 18 (35%) stage 3A, and eight (16%) stage 4A.
20% of cases including severe gastrointestinal bleeding in
one, cardiopulmonary complications in three, significant
Follow-up
but reversible hepatic failure in five, and abdominal wound
dehiscence in one.All cases were followed at 4-month intervals with serial
AFP levels, US and CT scanning. Recurrence of HCC in The mean hospital stay was 13 days (range 6–36 days).
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Fig. 2. Overall survival for the 51 cirrhotic patients with superveningFig. 1. Overall (–––) and disease-free (– – –) survival in 51 cirrhotic
patients with hepatocellular carcinoma following resection. hepatocellular carcinoma undergoing resection: the eﬀect of
microvascular invasion. (No vascular invasion [–––] vs vascular
invasion [– – –]: P<0.0001.)
Table 3. Recurrence of hepatocellular carcinoma for the 51 cirrhotic
patients with supervening HCC undergoing resection
Incidence 23 patients (45%)
Site
Liver 19 (83)
Liver/lung 3 (13)
Lung 1 (4)
Mean (SD) time of recurrence 16 (12)
(months)
Time to recurrence (months)
0–12 12 (52)
13–24 4 (17)
More than 24 7 (31)
Values in parentheses are percentages. SD: standard deviation.
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The mean follow-up was 28 months (range 4–60 months).
The 1-year, 3-year and 4-year overall and disease-free Fig. 3. Overall survival for the 51 cirrhotic patients with supervening
hepatocellular carcinoma undergoing resection. (Solitary [–––] vssurvival rates were 89, 53 and 53%, respectively, and 66, 34
multiple [– – –] tumours: P<0.01.)and 30%, respectively (Fig. 1).
Recurrent HCC was diagnosed in 23 patients (45%) with
12 patients (52% of recurrences) recurring within 1 year of
surgery and 22 patients (96% of recurrences) within 3 years. and 100, 73 and 73%, respectively, in those cases without
vascular invasion (P<0.0001) (Fig. 2).Recurrent disease was most frequently detected in the liver
parenchyma, usually as a solitary tumour near the resection The 1-year, 3-year and 4-year disease-free survival rates
for patients with vascular invasion were 40, 13 and 13%,margin.
Extrahepatic recurrences were detected in four cases respectively, and 79, 46 and 38%, respectively, in those cases
without vascular invasion (P<0.005).(17%), all presenting with solitary lung metastases (Table
3). Four patients with microscopic vascular invasion
developed recurrence within 1 year following surgery andTumour size did not aﬀect either overall survival or
disease-free survival. The 4-year overall survival rates for three-quarters of those with microvascular invasion (12
patients) died within 3 years of hepatectomy.tumours <2 cm, 2–5 cm and >5 cm in maximal diameter
were 50, 60 and 40%, respectively. The 4-year disease-free The 1-year, 3-year and 4-year overall survival rates for
patients with a solitary tumour were 92, 66 and 66%,survival rates for tumours <2 cm, 2–5 cm and >5 cm in
maximal diameter were 17, 36 and 27%, respectively. respectively, whereas equivalent survival rates for patients
with more than one tumour were 78, 11 and 11%, respectivelyHistologic vascular invasion was found to be a relevant
prognostic factor for overall and disease-free survival. The (P<0.01) (Fig. 3).
The 1-year, 3-year and 4-year disease-free survival rates1-year, 3-year and 4-year overall survival rates for patients
with vascular invasion were 67, 15 and 15%, respectively, for patients with a solitary tumour were 71, 41 and 35%,
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Discussion and conclusions
Strict follow-up of patients with cirrhosis, mainly by US
examination, has increased the frequency of diagnosis of
small resectable HCC.2,4 This is reflected in this series by the
fact that 74% of patients were asymptomatic and detected on
routine follow-up US. Hepatectomy appears to be relatively
safe even in cirrhotic patients with supervening HCC with
an overall mortality of 8% in our series. Moreover, the 5-
year survival in such patients is between 33 and 46% in
most Western countries1,14,15 and 25 and 33% in reported
Asian series.16–18
Intra-operative ultrasonography is a valuable tool not
only for detecting the tumour, but also for establishing
adequate resection margins sparing as much parenchyma
as possible.19–22 In this study, 24% of tumours were not
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found on careful inspection or palpation of the cirrhotic
Fig. 4. Overall survival for the 51 cirrhotic patients with supervening liver but were only located with IOUS examination.
hepatocellular carcinoma undergoing resection. (Symptomatic [–––] The introduction of limited hepatectomy using IOUS23,24vs asymptomatic [– – –] patients: P<0.05.)
has an acceptable morbidity in cirrhosis complicated by
supervening HCC.25–27 There has been considerable
improvement in the prediction of the safety of liver resection
in selected patients with cirrhosis and impaired hepaticTable 4. Multivariate analysis of prognostic variables aﬀecting
overall survival and disease-free survival in 51 cirrhotic patients reserve;28,29 however, tumour recurrence during follow-up in
following hepatic resection for hepatocellular carcinoma this group is common.17,23,30 The recurrence rate in this series
was 49% in patients surviving surgery, and was similar to
Variables R SE P RR IC
that of other series.3,18,31,32 The cumulative recurrence rate
at 3 years was 57% in our study and was similar to thatMicrovascular invasion
Overall survival 0.3043 0.4849 0.0002 6.2 2.4–16.1 reported by Belghiti et al.33 who found an overall
Disease-free survival 0.1728 0.3876 0.0062 2.9 1.4–6.2 intrahepatic recurrence of 60%, with a cumulative
Multiple tumour
intrahepatic recurrence rate of 81% at 3 years dependingOverall survival 0.1832 0.4708 0.0113 3.3 1.3–8.3
on the size of the original primary, the presence of a tumourDisease-free survival 0.0000 0.4275 0.1671 1.8 0.8–4.2
Symptomatic tumour capsule and the pre-operative AFP level.
Overall survival 0.1282 0.5147 0.0413 2.9 1.1–7.8 The majority of tumour recurrences in our study were
Disease-free survival 0.1073 0.4542 0.0423 2.5 1.1–6.1 intrahepatic and occurred within the first year after
resection, as reported by other authors.18,34 Most presentedR, regression coeﬃcient; SE, standard error; RR, relative risk;
as solitary nodules close to the original resection line.IC, confidence interval.
This has been a similar finding in other studies concerning
cirrhotics with supervening HCC35,36 as well as in HCC
patients without cirrhosis,37 where intrahepatic recurrence
most commonly follows small non-anatomical resections.respectively, compared with 44, 11 and 11%, respectively,
for patients presenting with multiple tumours (P<0.05). The most significant prognostic factors reported for
recurrence have included: more than one primary tumour,The 1-year, 3-year and 4-year overall survival rates for
patients with a symptomatic tumour were 80, 0 and 0%, tumour size greater than 2 cm in maximal diameter, the
presence of a tumour capsule, and vascular invasion.3,30,38–42respectively, whereas equivalent survival for patients with
an asymptomatic tumour were 91, 63 and 63%, respectively In the present series of cirrhotic subjects, tumour size was
not a significant prognostic factor and the presence of(P<0.05) (Fig. 4).
The 1-year, 3-year and 4-year disease-free survival rates tumour encapsulation did not reach significance. Vascular
invasion and symptomatic tumours were significantfor patients with a symptomatic tumour were 40, 0 and 0%,
compared with 73, 41 and 35%, respectively, for patients prognostic factors in multivariate analysis, which correlated
with recurrence. This highlights the importance of closewith an asymptomatic tumour (P<0.05).
To clarify the significance of each significant parameter follow-up in patients with cirrhosis in order to detect
asymptomatic tumours.by univariate analysis, multiple logistic regression analysis
was carried out with Cox’s proportional hazard model. If tumour recurrence occurs, there are several treatment
options43 depending on several parameters such as size andTable 4 shows the result of multivariate analysis assessing
vascular invasion, multiple tumour and symptomatic location of the tumour, number of tumour nodules and
functional hepatic reserve. One option is to repeat thetumour.
The type of cirrhosis, presence or absence of a tumour hepatic resection and survival in these cases has been as
high as 75% at 3 years.32 Ringe et al.44 have found a highcapsule, surgical resection margin or tumour grading did
not aﬀect either overall survival or disease-free survival on incidence of HCC recurrence with re-resection, and they
have proposed liver transplantation in cases of resectableunivariate analysis.
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